Research programme: inhaled therapeutics - MannKind/Receptor Life Sciences

Drug Profile

Research programme: inhaled therapeutics - MannKind/Receptor Life Sciences

Alternative Names: Epinephrine Technosphere®; Palonosetron Technosphere®

Latest Information Update: 23 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MannKind Corporation; Receptor Life Sciences
  • Class Antiarrhythmics; Antiemetics; Antihypotensives; Benzene derivatives; Bronchodilators; Catecholamines; Ethanolamines; Isoquinolines; Quinuclidines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Anaphylaxis; Nausea and vomiting

Most Recent Events

  • 05 Jun 2017 Research programme: inhaled therapeutics - MannKind/Receptor Life Sciences is available for licensing as of 05 Jun 2017. http://www.mannkindcorp.com
  • 21 Jan 2016 MannKind and Receptor Life Sciences agree to co-develop inhaled therapeutics for Pain, Neurological disorders and Inflammation
  • 21 Jan 2016 Early research in Anaphylaxis in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top